We are live on
!
Find out more
AE
Axon Enterprise Portfolio holdings
AUM
$19.1M
1-Year Est. Return
8.75%
This Fund
S&P 500
This Quarter
Est. Return
+30.82%
1 Year Est. Return
-8.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$198M
AUM Growth
–
Cap. Flow
+$173M
Cap. Flow
% of AUM
87.37%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
1
New
1
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cellebrite
CLBT
|
+$173M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cellebrite
CLBT
$3.01B
| $198M | 100% |
+9,000,000
| New | +$173M |
|
Similar funds
LFA
BIMC
IACCGIA
PMAM
SRHG
VAM
FS
MPW
Axon Enterprise's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Axon Enterprise, which disclosed 1 position worth $198M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Cellebrite: 9,000,000 shares worth $198M.
By sector, the portfolio is most concentrated in Technology at 100% of assets.
- Axon Enterprise's largest Q4 2024 buy was Cellebrite: 9,000,000 shares worth $198M.
- Axon Enterprise's ten largest holdings make up 100% of its $198M portfolio in Q4 2024.
- Axon Enterprise disclosed 1 position in Q4 2024, its first 13F filing on record.
Based on Axon Enterprise's 13F filing for Q4 2024, filed 14 Feb 2025.